Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Nursing Perspectives
Video Expert Opinion
Sign in
Join now
featured
Published in Metastatic Breast Cancer and
1 other channel

Expert Opinion / Interview · September 27, 2016

Advances in Genomic Testing and Computational Biology for Breast Cancer

Interview by
Farzanna S Haffizulla MD, FACP, FAMWA
Interview with
Kimberly L Blackwell MD

 

 Save  Recommend
 Share

Additional Info

  1. Piccart M, Rutgers E, van’t Veer L, et al. Primary analysis of the EORTC 10041/ BIG 3-04 MINDACT study: a prospective, randomized study evaluating the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes. Paper presented at: 2016 American Association of Cancer Research Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. Abstract CT039.

  2. Sparano JA, Gray RJ, Makower DF, et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer N Engl J Med. 2015;373(21):2005-2014.

Disclosure statements are available on the authors' profiles:

Kimberly Blackwell MD

Further Reading

Related Videos